BUFORD,Theragenics announced Monday that it has received Food and Drug Administration approval to launch a clinical trial for its TheraSight product.
TheraSight is a proposed three-dose radiation treatment for treatment of a certain type of cancer that causes blindness. Thirty patients will be enrolled for the study, the company said.
The company is targeting the “wet” version of age-related macular degeneration (AMD), the leading cause of blindness in the United States. There also is a “dry” version. The wet version is caused by abnormal blood vessels.